UK Markets close in 2 hrs 23 mins

Biophytis SA (BPTS)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
5.17-0.14 (-2.65%)
At close: 11:54AM EST
Full screen
Trade prices are not sourced from all markets
Previous close5.31
Open5.06
Bid5.04 x 1100
Ask5.23 x 1000
Day's range5.06 - 5.17
52-week range5.06 - 18.50
Volume1,443
Avg. volume3,368
Market cap58.819M
Beta (5Y monthly)1.11
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Biophytis to Restate Previously Issued Financial Statements

    PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announced that the Company’s previously iss

  • Globe Newswire

    Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

    PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces it will host a virtual key opinion leader (KOL) event on October

  • Globe Newswire

    Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

    PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the issuance of 240 Bonds Redeemable in Cash and New and Exist